about
Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice.A learning activity to introduce undergraduate students to bioethics in human clinical research: a case study.Sex-Divergent Clinical Outcomes and Precision Medicine: An Important New Role for Institutional Review Boards and Research Ethics Committees.Sunitinib Possible Sex-Divergent Therapeutic Outcomes.A systematic review of the relationship factor between women and health professionals within the multivariant analysis of maternal satisfaction.Reduced exposure of imatinib after coadministration with acetaminophen in miceCoadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment.Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis.Bioequivalence Study of Two Long-Acting Formulations of Oxytetracycline Following Intramuscular Administration in Bovines.Is the precautionary principle adaptable to emergency scenarios to speed up research, risking the individual informed consent?Commentary: Grand challenge: ELSI in a changing global environment.Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.Histopathological study of the hepatic and renal toxicity associated with the co-administration of imatinib and acetaminophen in a preclinical mouse model.HPLC determination of imatinib in plasma and tissues after multiple oral dose administration to mice.Potential protective effect of sunitinib after administration of diclofenac: biochemical and histopathological drug-drug interaction assessment in a mouse model.Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system.Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.Is the pharmacokinetics of bupivacaine equivalent after lumbar epidural administration through a needle or a catheter in male and female adults?Diclofenac sex-divergent drug-drug interaction with Sunitinib: pharmacokinetics and tissue distribution in male and female mice.Sunitinib-paracetamol sex-divergent pharmacokinetics and tissue distribution drug-drug interaction in mice.Sunitinib DDI with paracetamol, diclofenac, mefenamic acid and ibuprofen shows sex-divergent effects on the tissue uptake and distribution pattern of sunitinib in mice.Erratum to: Sunitinib Possible Sex-Divergent Therapeutic Outcomes.Sunitinib-ibuprofen drug interaction affects the pharmacokinetics and tissue distribution of sunitinib to brain, liver, and kidney in male and female mice differently.Sunitinib tissue distribution changes after coadministration with ketoconazole in mice.Toxoplasma gondii: determination of the onset of chronic infection in mice and the in vitro reactivation of brain cysts.Ethical Challenges of Germline Genetic EnhancementMoral enhancement, at the peak of pharmacology and at the limit of ethics
P50
Q34246117-7E846C11-182C-4274-A684-110F18C2CDD3Q38369554-16580734-0F97-4374-AFDB-D6AB6F424A96Q38635940-6C18A607-C21A-487B-BFA0-6F6A8C96ACE8Q38869600-34F97E37-879B-495B-A3CD-165261B66BE0Q38934651-CEC58391-7165-4423-85C8-631B424FFE00Q40729511-89CCF277-911C-4634-9EAD-B4DFE2B8FDABQ41648736-EC30D539-3FD7-4A02-90CC-C7D0525FED97Q41968777-C5AB7249-F1AF-4AE0-B910-662B0E7D66CCQ42060343-A7B7B36D-9ACD-451F-B9C7-3483246540F5Q42250875-5A4F85AD-E1BD-438C-9BF7-E94AB43A3920Q42368384-479DF4AB-7D69-4607-B605-E83F53FCFAA5Q42970920-1D769817-5C8D-48BD-8051-A8F1659E9019Q42976363-3EE46386-B72E-4D0C-8E96-BBF58E3156C2Q43196302-8BD2CC18-26FD-4329-9013-17D033F5FE72Q43580967-CF350059-FBB5-4AB5-9FC2-78003390542FQ44062795-0D38E965-B8CA-4C9E-A928-8433FB6EE6AEQ44585287-A2CFDD0E-A34F-4A84-8E2C-F9FB913C497BQ47735533-DF382D10-BCA6-409A-A6FB-BCB9E5B3A1DDQ47831824-130E9294-E4F3-466B-B430-5418E93BEFCEQ47895186-75F35AB4-8655-46A8-8E7A-D37E2C1DEEFDQ48029427-63E1E8D3-EF51-45E1-8EF2-614A3F8B7C10Q48107861-933382A0-2C1D-4076-A9B8-9FF4E1DF869EQ48159588-431DB9F2-E053-4105-A19D-11D4FBA0F4C7Q48341764-0D916BAE-9092-4CF5-AC65-CFCCB55CBB7BQ48821154-7407F281-0FA5-4D0E-BCF5-1A68C11E89ACQ90266341-3A34CC48-C0DA-4868-A799-2BC288344FCBQ91539653-1ACD4AAC-830D-49DA-B6DF-98B382C0F310
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-8721-2393
@en
name
Ignacio Segarra
@ast
Ignacio Segarra
@en
Ignacio Segarra
@es
Ignacio Segarra
@nl
type
label
Ignacio Segarra
@ast
Ignacio Segarra
@en
Ignacio Segarra
@es
Ignacio Segarra
@nl
prefLabel
Ignacio Segarra
@ast
Ignacio Segarra
@en
Ignacio Segarra
@es
Ignacio Segarra
@nl
P106
P21
P31
P496
0000-0002-8721-2393